Böbrek Nakli Alıcılarında Cd4+ Ve Cd8+ T Lenfositlerin Vitamin D Reseptör İçerikleri ve Reseptör Ekspresyon Hızları

Yıl 2022, , 25 - 36, 14.01.2022

Sultan Ural Edebali , Sadi Köksoy , Vural Taner Yılmaz , Sebahat Özdem , Fatih Yılmaz , Hasan Sözel , Fettah Fevzi Ersoy

https://doi.org/10.20515/otd.974905

Öz

Bu çalışma, kronik allogreft disfonksiyonu (KAD) olan böbrek nakli (BN) alıcılarının CD4+ ve CD8+ lenfositlerinde D vitamini reseptörü (VDR) ekspresyonunu ve hücre içi VDR miktarlarını değerlendirmeyi amaçlamaktadır.Toplam 43 hasta (Grup 1:BN hastaları=29 hasta, böbrek biyopsisi ile KAD kanıtlanmış 15 hasta (Grup 1a), böbrek fonksiyonu stabil 14 hasta (Grup 1b), Grup 2:Kontrol grubu=14 sağlıklı birey) bu çalışmaya dahil edilmiştir. 25-hidroksikolekalsiferol, 1.25 dihidroksikolekalsiferol seviyeleri ölçüldü. Deneklerin CD4+ ve CD8+ tip T lenfositleri arasında VDR eksprese eden hücre sayısı, bu hücre gruplarının %'si olarak belirlendi. Hücre başına ortalama VDR molekülü içeriği ölçülmüş ve ortalama floresan yoğunlukları (MFI) olarak ifade edilmiştir.Grup 1 ve Grup 2 arasında 25-hidroksikolekalsiferol, 1.25 dihidroksikolekalsiferol düzeyleri ve CD4+ ve CD8+ hücrelerinde VDR eksprese eden hücrelerin yüzdeleri açısından fark bulunmadı (p>0.05). BN hastalarında CD4+/VDR(MFI) ve CD8+/VDR(MFI) değerleri sağlıklı kişilere göre daha yüksekti (p<0,001). BN hasta alt grupları karşılaştırıldığında, CD4+/VDR(%), CD8+/VDR(%), CD4+/VDR(MFI) ve CD8+/VDR(MFI) değerleri açısından istatistiksel olarak anlamlı fark yoktu (p>0.05).Bu çalışma, BN uygulanan hastaların T lenfositlerinde VDR'nin değişmediğini, ancak hücrelerdeki VDR içeriğinin serum 25-hidroksikolekalsiferol ve 1.25 dihidroksikolekalsiferol düzeylerinden bağımsız nedenlerle arttığını gösterdi.

Anahtar Kelimeler

CD4+ lenfositler, CD8+ lenfositler, 25(OH)D3, 1.25(OH)2D3, Vitamin D reseptörü, Böbrek nakli

Destekleyen Kurum

Çalışmamıza herhangi bir kurum desteği olmamıştır.

Vitamin D Receptor Contents and Receptor Expresslon Rates of Cd4+ and Cd8+ T Lymphocytes Ln Renal Transplant Reclplents

Öz

This study aims to evaluate the vitamin D receptor (VDR) expression and intracellular amounts of VDRs in CD4+ and CD8+ lymphocytes of renal transplant (RT) recipients with chronic allograft dysfunction (CAD). A total of 43 patients (Group 1:RT patients=29 patients, 15 patients CAD proven by renal biopsy (Group 1a), 14 patients stable renal function (Group 1b), Group 2:Control group=14 healthy individuals) have been enrolled in this study. 25-hydroxycholecalciferol, 1.25 dihydroxycholecalciferol levels were measured. The number of cells expressing VDR among the CD4+ and CD8+ type T lymphocytes of the subjects was determined as % of those cell groups. The mean VDR molecule contents per cell have been measured and expressed as mean fluorescence intensities (MFI). No difference was found between Group 1 and Group 2 in terms of their 25-hydroxycholecalciferol, 1.25 dihydroxycholecalciferol levels, and the percentages of the cells expressing VDR in CD4+ and CD8+ cells (p>0.05). CD4+/VDR(MFI) and CD8+/VDR(MFI) values were higher in RT patients than healthy subjects (p<0.001). When the RT patient subgroups compared, there were no statistically significant differences regarding CD4+/VDR(%), CD8+/VDR(%), CD4+/VDR(MFI) and CD8+/VDR(MFI) values (p>0.05). This study showed VDR in T lymphocytes of patients who had RT did not change, but the VDR content in the cells increased due to reasons independent of serum 25-hydroxycholecalciferol and 1.25 dihydroxycholecalciferol levels.

Anahtar Kelimeler

CD4+ lymphocytes, CD8+ lymphocytes, 25(OH)D3, 1.25(OH)2D3, Vitamin D receptor, Renal transplantation

Kaynakça

• Brewster UC, Perazella MA. The renin-angiotensin-aldosterone system and the kidney: Effects on kidney disease. Am J Med. 2004;116(4):263-72.
• Courbebaisse M, Souberbielle JC, Thervet E. Potential nonclassical effects of vitamin D in transplant recipients. Transplantation. 2010;89(2):131-7.
• Makibayashi K, Tatematsu M, Hirata M, et al. A vitamin D analog ameliorates glomerular injury on rat glomerulonephritis. Am J Pathol. 2001;158(5):1733-41.
• Tan X, He W, Liu Y. Combination therapy with paricalcitol and trandolapril reduces renal fibrosis in obstructive nephropathy. Kidney Int. 2009;76(12):1248-57.
• Penna G, Adorini L. 1α,25-Dihydroxyvitamin D 3 Inhibits Differentiation, Maturation, Activation, and Survival of Dendritic Cells Leading to Impaired Alloreactive T Cell Activation . J Immunol. 2000;164(5):2405-11.
• Tiosano D, Weisman Y, Hochberg Z. The role of the vitamin D receptor in regulating vitamin D metabolism: A study of vitamin D-dependent rickets, type II. J Clin Endocrinol Metab. 2001;86(5):1908-12.
• Hullett DA, Laeseke PF, Malin G, et al. Prevention of chronic allograft nephropathy with vitamin D. Transpl Int. 2005;18(10):1175-86.
• Fletcher JT, Nankivell BJ, Alexander SI. Chronic allograft nephropathy. Pediatr Nephrol. 2009;24:1465–71 .
• Haas M, Sis B, Racusen LC, et al. Banff 2013 meeting report: Inclusion of C4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant. 2014;14(2):272-83.
• Moe SM, Drüeke TB. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder (CKD–MBD). Kidney Int Suppl. 2009;(113):1-130.
• Stavroulopoulos A, Cassidy MJD, Porter CJ, Hosking DJ, Roe SD. Vitamin D status in renal transplant recipients. Am J Transplant. 2007;7(11):2546-52.
• Wile B, Yoo E, Alvarez Elías AC, et al. Does vitamin d affect chronic renal allograft function in pediatric transplant patients? Ann Transplant. 2018;23:252-7.
• KDIGO. KDIGO - Diagnosis, evaluation, prevention and treatment of CKD-MBD. Am J Transplant. 2009;9(3):1-155.
• Walsh SB, Altmann P, Pattison J, et al. Effect of Pamidronate on Bone Loss After Kidney Transplantation: A Randomized Trial. Am J Kidney Dis. 2009;53(5):856-65.
• Wissing KM, Broeders N, Moreno-Reyes R, Gervy C, Stallenberg B, Abramowicz D. A controlled study of vitamin D3 to prevent bone loss in renal-transplant patients receiving low doses of steroids. Transplantation. 2005;79(1):108-15.
• O’Herrin JK, Hullett DA, Heisey DM, Sollinger HW, Becker BN. A retrospective evaluation of (1,25-Dihydroxyvitamin D3 and its potential) effects on renal allograft function. Am J Nephrol. 2002;22(5-6):515-20.
• Sezer S, Uyar M, Arat Z, Özdemir FN, Haberal M. Potential effects of 1,25-dihydroxyvitamin D(3) in renal transplant recipients. Transplant Proc. 2005;37(7):3109-11.
• Sezer S, Yavuz D, Canoz MB, Ozdemir FN, Haberal M. Vitamin D Status, Bone Mineral Density, and Inflammation in Kidney Transplantation Patients. Transplant Proc. 2009;41(7):2823-5.
• Tanaci N, Karakose H, Guvener N, et al. Influence of 1,25-dihydroxyvitamin D3 as an immunomodulator in renal transplant recipients: A retrospective cohort study. Transplant Proc. 2003;35(8):2885-7.
• Uyar M, Sezer S, Arat Z, et al. 1,25-Dihydroxyvitamin D(3) Therapy Is Protective for Renal Function and Prevents Hyperparathyroidism in Renal Allograft Recipients. Transplant Proc. 2006;38(7):2069-73.
• Wesseling-Perry K, Tsai EW, Ettenger RB, Jüppner H, Salusky IB. Mineral abnormalities and long-term graft function in pediatric renal transplant recipients: A role for FGF-23? Nephrol Dial Transplant. 2011;26(11):3779-84.
• Redaelli CA, Wagner M, Günter-Duwe D, et al. 1α,25-Dihydroxyvitamin D3 shows strong and additive immunomodulatory effects with cyclosporine A in rat renal allotransplants. Kidney Int. 2002;61(1):288-96.
• Hsu CH, Patel S. Uremic plasma contains factors inhibiting 1α-hydroxylase activity. J Am Soc Nephrol. 1992;3(4):947-52.
• Wesseling-Perry K, Salusky IB. Is replacement therapy with nutritional and active forms of vitamin D required in chronic kidney disease mineral and bone disorder? Curr Opin Nephrol Hypertens. 2009;18(4):308–14.
• Taal MW, Thurston V, McIntyre NJ, Fluck RJ, McIntyre CW. The impact of vitamin D status on the relative increase in fibroblast growth factor 23 and parathyroid hormone in chronic kidney disease. Kidney Int. 2014;86(2):407-13.
• Lee C Te, Ng HY, Lien YH, et al. Effects of cyclosporine, tacrolimus and rapamycin on renal calcium transport and vitamin D metabolism. Am J Nephrol. 2011;34(1):87-94.
• Grenet O, Bobadilla M, Chibout SD, Steiner S. Evidence for the impairment of the vitamin D activation pathway by cyclosporine A. Biochem Pharmacol. 2000;59(3):267-72.
• Hewison M, Freeman L, Hughes S V., et al. Differential Regulation of Vitamin D Receptor and Its Ligand in Human Monocyte-Derived Dendritic Cells. J Immunol. 2003;170(11):5382-90.
• Özkan B. Nutritional rickets. J Clin Res Pediatr Endocrinol. 2010;2(4):137-43.
• Issa LL, Leong GM, Eisman JA. Molecular mechanism of vitamin D receptor action. Inflamm Res. 1998;47(12):451-75.
• Ferrari S, Bonjour JP, Rizzoli R. The vitamin D receptor gene and calcium metabolism. Trends Endocrinol Metab. 1998;9(7):259–65.
• Bouillon R, Carmeliet G, Daci E, Segaert S, Verstuyf A. Vitamin D metabolism and action. Osteoporos Int. 1998;8(2):13-9.
• Wortsman J, Matsuoka LY, Chen TC, Lu Z, Holick MF. Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr. 2000;72(3):690-3.